Page last updated: 2024-08-16

pioglitazone and gw 4064

pioglitazone has been researched along with gw 4064 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Angioni, C; Geisslinger, G; Goebel, T; Heering, J; Kahnt, A; Kaiser, A; Merk, D; Paulke, A; Proschak, E; Rotter, M; Schmidt, J; Steinhilber, D; Weiser, T; Weizel, L; Wittmann, S; Wurglics, M1
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y1

Reviews

1 review(s) available for pioglitazone and gw 4064

ArticleYear
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
    Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10

    Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary

2020

Other Studies

2 other study(ies) available for pioglitazone and gw 4064

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
    Journal of medicinal chemistry, 2017, 09-28, Volume: 60, Issue:18

    Topics: Animals; Anti-Inflammatory Agents; Drug Discovery; Enzyme Inhibitors; Epoxide Hydrolases; HeLa Cells; Hep G2 Cells; Humans; Liver; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship

2017